News on November 28, Hugang Zhongke International Biotechnology Co.
, Ltd.
announced that the company completed a series B financing
of nearly 100 million yuan led by AstraZeneca CICC Medical Industry Fund.
This round of funding will be mainly used to promote the construction of key resources required for preclinical evaluation of innovative drugs/devices and the development layout
of Hong Kong and international business.
In fact, in the first three quarters of 2022, the number of financing events in the field of innovative drugs accounted for a significant decline in the total number of financing events in the medical and health field, and the industry believes that the industry is facing financial pressure
.
However, in the long run, there are still new opportunities
in the innovative drug industry.
At present, the seventh batch of national centralized procurement has entered the formal implementation stage, most provinces and cities have announced the specific time of bidding, and the selected 61 varieties are expected to usher in a new round of volume
.
The eighth batch of centralized procurement is also about to come out, and the policy rules may be more relaxed, and the industry expects that under the normalization of centralized procurement, the innovative drug market is expected to usher in greater market prospects
.
In addition, the Center for Drug Review (CDE) of the State Food and Drug Administration recently issued a notice on the "Technical Guidelines for Clinical R&D of Bispecific Antibody Antitumor Drugs", and continuously solicited public solicitations on the "Technical Guidelines for Clinical Trials of Lupus Nephritis Treatment Drugs", "Technical Guidelines for Clinical Trials of Drugs for the Treatment of Chronic Kidney Disease", "Technical Guidelines for Clinical Development of New Chinese Medicine Compound Preparations Related to the Treatment of Malignant Tumors", "Technical Guidelines for Clinical Trial Design of Multiple Sclerosis Therapy Drugs", " A number of guiding principles, such as the technical guidelines for clinical trials of dry eye treatment drugs and the technical guidelines for clinical trials of atopic dermatitis treatment drugs, aim to provide new research and development ideas and technical suggestions
for new drug research and development.
Guangdong Securities newly released pharmaceutical industry weekly report believes that the pharmaceutical market is a rigid demand market, with the reform of the medical and health system, optimization of review and approval to encourage innovation, drug marketing authorization system, two-invoice system, medical insurance payment and other policies rapidly advanced, the industry competition pattern has undergone major changes, local innovation is facing new challenges and opportunities
.
For innovative drug investment, Guangdong Securities recommends investors to pay attention to two core logics
.
The first is to focus on big pharma-type enterprises that have accumulated advantages in the era of generic drugs and seek innovation and transformation, which have strong endogenous profits, more stable growth, and transformation and innovation have technical and cost advantages
.
The second is to pay attention to biotech enterprises with rich R&D pipelines, existing products on the market and active layout of internationalization, the formation of product matrix of such enterprises, innovative research and development, BD capabilities, and commercial transformation have been basically verified, showing huge market potential
.
GF Securities also mentioned the above two types of enterprises, the bank pointed out that if Biotech truly becomes an international Big Pharma, its core is still to build product competitiveness, develop new drugs for unmet clinical needs, and also have global development and even commercialization capabilities
.
The bank said that for biotech companies, the international development system is actually a double-edged sword, with huge operating costs and the constant need for new projects to keep running
.
From early authorization to independent clinical development and commercialization, the road to the sea of domestic pharmaceutical companies needs to be gradual and gradually
expanded.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
